Sermorelin, CJC-1295/ipamorelin or tesamorelin?
Similar hormone pathways do not make these treatments interchangeable. Start with the reason for treatment and the evidence for the exact preparation.
The short answer
These drugs have different formulations and evidence. Tesamorelin has an approved product for a specific HIV-associated condition. Neither that approval nor hormone-marker studies establish a general recovery or anti-aging benefit for the compounded options here.
Side by side
| Sermorelin | CJC-1295/ipamorelin | Tesamorelin | |
|---|---|---|---|
| Approach | Growth-hormone-releasing hormone analogue | A two-ingredient secretagogue blend | Growth-hormone-releasing factor analogue |
| Relevant research | Related GHRH studies in defined populations | Separate ingredient studies, not this blend | Approved product studied in HIV-associated lipodystrophy |
| Evidence limit | No general longevity result established here | Hormone changes are not proof of recovery benefits | Approved indication is not general weight loss |
What the evidence shows
The GHRH cognition trial, short long-acting CJC-1295 studies and tesamorelin labeling answer different questions. Egrifta WR targets excess abdominal fat in adults with HIV-associated lipodystrophy and is not indicated for weight-loss management. Its evidence does not establish equivalence for compounded tesamorelin.
Read: Vitiello et al. GHRH and cognition in healthy older adults; Teichman et al. Long-acting CJC-1295 in healthy adults; Beck et al. IV ipamorelin after bowel surgery; Egrifta WR prescribing information; FDA: Compounding questions and answers.
What matters for your decision
Ask which goal or diagnosis supports the recommendation, the exact formulation and what follow-up will determine whether it is helping. Treat a change in GH or IGF-1 as a measurement to interpret, not an automatic benefit.
Questions
Is there a simple strongest-to-weakest ranking?
No useful ranking follows from these studies. They do not directly compare the offered products for the same patient-centered outcome.
Sources
- Vitiello et al. GHRH and cognition in healthy older adults
Neurobiology of Aging, 2006. Six-month GHRH trial; does not establish general anti-aging benefits.
- Teichman et al. Long-acting CJC-1295 in healthy adults
JCEM, 2006. Short studies of GH and IGF-1 responses; not a trial of the CJC-1295/ipamorelin blend.
- Beck et al. IV ipamorelin after bowel surgery
International Journal of Colorectal Disease, 2014. Different route, population and outcome from wellness use.
- Egrifta WR prescribing information
DailyMed. Tesamorelin for excess abdominal fat in adults with HIV-associated lipodystrophy.
- FDA: Compounding questions and answers
The distinction between compounded medications and FDA-approved drug products.
